The company states: "Aravive announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology – and vascular endothelial growth factor tyrosine kinase inhibitor-based therapies."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARAV:
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
- Aravive initiated with a Buy at EF Hutton
- Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
- Aravive complete enrollment in Phase 3 AXLerate-OC trial
